デフォルト表紙
市場調査レポート
商品コード
1466240

経皮ドラッグデリバリーシステム市場:タイプ、用途、エンドユーザー別-2024~2030年の世界予測

Transdermal Drug Delivery System Market by Type (Transdermal Patches, Transdermal Semisolids), Application (Cardiovascular Diseases, Central Nervous System Disorders, Hormonal Applications), End User - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.74円
経皮ドラッグデリバリーシステム市場:タイプ、用途、エンドユーザー別-2024~2030年の世界予測
出版日: 2024年04月17日
発行: 360iResearch
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

経皮ドラッグデリバリーシステム市場規模は、2023年に69億8,000万米ドルと推定され、2024年には73億2,000万米ドルに達し、CAGR 5.06%で2030年には98億7,000万米ドルに達すると予測されます。

経皮ドラッグデリバリーは、皮膚からの薬剤の制御放出を促進する治療法の製造、流通、応用からなります。この革新的なアプローチは、患者のコンプライアンス向上、副作用の軽減、薬物動態プロファイルの改善など、従来の経口または静脈内薬剤投与と比較して多くの利点を提供します。TDDSには、受動拡散システム、イオントフォレーシス、マイクロニードル、超音波を介した技術など、さまざまな技術が含まれます。高齢化人口の増加や慢性疾患の蔓延により、より実用的で利便性の高いドラッグデリバリー法が必要とされています。さらに、ナノテクノロジーと材料科学の進歩により、患者に刺激や不快感を与えることなく生体膜を通過する優れた薬物透過性を提供する洗練された経皮パッチの開発が可能になった。しかし、複雑な経皮システムの製造に伴う高い開発コストや製品回収の発生は、ヘルスケア分野での使用に悪影響を及ぼす可能性があります。また、先進的なドラッグデリバリービークルは、水溶性薬物のバイオアベイラビリティと溶解度を改善し、より効果的な経皮ドラッグデリバリー戦略を可能にする有望な可能性を示しています。

主な市場の統計
基準年[2023] 69億8,000万米ドル
予測年[2024] 73億2,000万米ドル
予測年 [2030] 98億7,000万米ドル
CAGR(%) 5.06%

タイプ経皮パッチの継続的な規制および政府承認

経皮パッチは、粘着剤でコーティングされた薬用パッチで、特定の薬物投与量を皮膚から血流に長期間にわたって送達するように設計されています。従来の経口および非経口ドラッグデリバリーシステムと比較して、患者のコンプライアンス向上、副作用の軽減、有効成分の放出制御など、いくつかの利点があります。薬物内包パッチ、マトリックスパッチ、マイクロニードルパッチ、リザーバー膜パッチなどがあり、医療上の要求に応じて使用されます。経皮パッチが好まれるのは、主に非侵襲的な性質と貼付の容易さによるものです。錠剤を飲み込むことが困難な患者や、薬の吸収に影響を及ぼす胃腸の問題を抱える患者に適しています。経皮半固形剤には、皮膚から全身循環に吸収される薬剤を配合したゲル、クリーム、軟膏があります。これらの剤形には、貼付や剥離が容易であること、特定の症状に対して全身性の副作用を伴わない局所的な治療が可能であること、処方の柔軟性などの利点があります。経皮吸収型パッチは、半固形製剤に比べ、放出制御機構が備わっているため、より安定した薬物放出が可能です。さらに、パッチは半固形剤よりも皮膚表面への接着性に優れているため、ゲルやクリームを頻繁に塗り直す必要があります。

応用例心血管疾患の管理における低侵襲ドラッグデリバリーシステムの必要性

経皮ドラッグデリバリーシステムは、副作用が少なく血漿中の薬物濃度を一定に保つことができるため、狭心症や高血圧症などの心血管系疾患の治療に好まれています。ニトログリセリンパッチは狭心症患者に広く使用されており、頻繁な経口投与を必要とせず、持続的な緩和を提供しています。TDDSは、薬物濃度を一定に保つことにより、パーキンソン病やアルツハイマー病などの中枢神経系疾患の管理にも有効です。持続的な投与により、経口薬で観察される変動が最小化され、ブレークスルー症状や副作用につながる可能性があります。TDDSのホルモン用途には、避妊、ホルモン補充療法(HRT)、テストステロン補充などがあります。経皮パッチは、ホルモンレベルを安定に保ち、副作用を軽減し、患者のコンプライアンスを向上させるという利点があります。経皮吸収型システムは、全身的な副作用を最小限に抑えながら、鎮痛薬を患部に長時間直接投与することができるため、筋骨格系障害やがんに関連した疼痛を含む慢性疼痛の管理で人気を博しています。経皮エストロゲン療法は、更年期症状に対するホルモン補充療法や閉経後女性の骨粗鬆症管理に不可欠です。

エンドユーザー:薬剤の自己投与が好まれるため、在宅介護の現場で実施可能なドラッグデリバリーシステムが求められています。

経皮ドラッグデリバリーシステムは、スキンケアのための特定の革新的なクリニックで利用され、より効果的な医療システムに導入されています。ドラッグデリバリーに対する理解が深まり、医師、エンジニア、科学者がこの技術を進歩させようと努力を続けていることから、超音波を利用した経皮デリバリープラットフォームは臨床応用に一歩近づくと期待されています。臨床的なインパクトは、薬剤を安全かつ効果的に投与し、低コストで使いやすく、家庭での自己投与が可能な経皮デリバリー・システムに依存しています。経皮ドラッグデリバリーは、そのユニークで有利な特性により、病院環境における数多くの病気の治療において、従来の薬物投与経路よりも将来的な利点をもたらすことから、最近人気が高まっています。病院や診療所は、地方、特に高齢者の患者を対象としています。これらの薬剤師は、薬物相互作用のリスクが高い患者や、自分の状態をコントロールできないために病気を併発する患者を支援しています。

地域別洞察

経皮ドラッグデリバリー市場は、医療インフラと研究開発活動が確立されている南北アメリカで新興国市場として発展しています。南北アメリカの規制機関は、新製品を承認する際に標準ガイドラインの遵守を徹底しており、その結果、革新的な経皮技術が開発されています。APAC地域では、可処分所得の増加、人口の高齢化、効率的な治療の必要性から、先進ヘルスケア技術に対する需要が高まっています。EMEA地域では、製薬業界の存在、医療支出の増加、経皮システムの製造能力の急速な拡大により、経皮ドラッグデリバリーシステム市場が成長しています。さらに、個別化医療や標的療法の採用が増加していることから、特定の患者集団や病状に合わせたTDDSシステムのさらなる普及が見込まれています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは経皮ドラッグデリバリーシステム市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、経皮ドラッグデリバリーシステム市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1.経皮ドラッグデリバリーシステム市場の市場規模および予測は?

2.経皮ドラッグデリバリーシステム市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3.経皮ドラッグデリバリーシステム市場の技術動向と規制枠組みは?

4.経皮ドラッグデリバリーシステム市場における主要ベンダーの市場シェアは?

5.経皮ドラッグデリバリーシステム市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 慢性疾患の蔓延と効果的なドラッグデリバリーの必要性
      • 第3世代の採用が急増経皮ドラッグデリバリーシステム
    • 抑制要因
      • パッチの使用に伴う刺激や皮膚の敏感さに関する懸念
    • 機会
      • 経皮ドラッグデリバリーシステムにおける進行中の研究開発
      • 製薬企業とTDDSベンダー間の無機的成長戦略
    • 課題
      • 経皮吸収システムと製品リコールによる薬剤の失敗の可能性のあるリスク
  • 市場セグメンテーション分析
    • タイプ:経皮パッチの規制および政府による承認が進行中
    • 応用:心血管疾患の管理のための低侵襲性ドラッグデリバリーシステムの必要性
    • エンドユーザー:薬剤の自己投与が好まれるため、在宅ケアの環境で実施できるドラッグデリバリーシステムの需要が高まっています。
  • 市場動向分析
    • アメリカ地域における市場参入企業の潜在力と規制承認の急増
    • アジア太平洋地域におけるヘルスケア費の急増と海外企業の参入
    • EMEA地域における継続的な調査活動と慢性疾患の負担の増大。
    • 電子皮膚による経皮ドラッグデリバリーの革命
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制枠組みの分析

第6章 経皮ドラッグデリバリーシステム市場:タイプ別

  • 経皮パッチ
  • 経皮吸収型半固形剤

第7章 経皮ドラッグデリバリーシステム市場:用途別

  • 心血管疾患
  • 中枢神経系疾患
  • ホルモンの応用
  • 疼痛管理
  • 経皮エストロゲン療法

第8章 経皮ドラッグデリバリーシステム市場:エンドユーザー別

  • 在宅ケア設定
  • 病院・クリニック

第9章 南北アメリカの経皮ドラッグデリバリーシステム市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の経皮ドラッグデリバリーシステム市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの経皮ドラッグデリバリーシステム市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス、2023
  • 競合シナリオ分析
    • 呂業薬の週2回投与リバスチグミン経皮パッチが中国でアルツハイマー病治療薬として承認
    • サティオ、在宅経皮ドラッグデリバリーデバイスの開発で350万米ドルの契約を獲得
    • LTS、ソレルウェアラブル注射デバイス事業の買収により高分子ドラッグデリバリーへの参入を完了
    • DifGen PharmaceuticalsがAvevaドラッグデリバリーServices Inc.を買収
    • ザイダス・ライフサイエンス社、エストラジオール経皮吸収システムの販売について米国FDAから最終承認を取得
    • キンデバがメリディアンと合併し、医薬品と医療機器の組み合わせに特化した世界CDMOを設立
    • LTSローマンが無針出産専門企業への投資を主導
    • ラブファーマ、経皮オピオイド使用障害治療薬プレーヤーの買収に動く
    • コリウム、アルツハイマー型認知症患者向けにADLARITY(ドネペジル経皮吸収システム)を発売
    • Lowensteinは、Pharma Tech LTS Lohmann Therapy Systems, Corp.のTapemark Inc.買収を代理します。

第13章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET RESEARCH PROCESS
  • FIGURE 2. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET DYNAMICS
  • FIGURE 7. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY MATRIX PATCHES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY MATRIX PATCHES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY MICRONEEDLE PATCHES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY MICRONEEDLE PATCHES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY RESERVOIR MEMBRANE PATCHES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY RESERVOIR MEMBRANE PATCHES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY GELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY GELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY OINTMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY SPRAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY SPRAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY HORMONAL APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY HORMONAL APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL ESTROGEN THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL ESTROGEN THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 277. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 287. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 297. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL
目次
Product Code: MRR-433C4187C49A

[180 Pages Report] The Transdermal Drug Delivery System Market size was estimated at USD 6.98 billion in 2023 and expected to reach USD 7.32 billion in 2024, at a CAGR 5.06% to reach USD 9.87 billion by 2030.

Transdermal drug delivery comprises the production, distribution, and application of therapeutic methods that facilitate the controlled release of medications through the skin. This innovative approach offers numerous advantages over conventional oral or intravenous drug administration, such as increased patient compliance, reduced side effects, and improved pharmacokinetic profiles. The TDDS encompasses various technologies, including passive diffusion systems, iontophoresis, microneedles, and ultrasound-mediated techniques. The increase in the aging population and the growing prevalence of chronic diseases necessitate more practical and convenient drug delivery methods. Furthermore, advancements in nanotechnology and materials science have enabled the development of sophisticated transdermal patches that offer superior drug permeation across biological membranes without causing irritation or discomfort to patients. However, high development costs associated with producing complex transdermal systems and incidences of product recalls may adversely impact their use in the healthcare sector. Besides, advanced drug delivery vehicles demonstrate promising potential to improve the bioavailability and solubility of water-soluble drugs, enabling more effective transdermal drug delivery strategies.

KEY MARKET STATISTICS
Base Year [2023] USD 6.98 billion
Estimated Year [2024] USD 7.32 billion
Forecast Year [2030] USD 9.87 billion
CAGR (%) 5.06%

Type: Ongoing regulatory and government approvals for transdermal patches

Transdermal patches are adhesive-coated, medicated patches designed to deliver a specific drug dosage through the skin and into the bloodstream over an extended period. They offer several advantages over conventional oral and parenteral drug delivery systems, such as improved patient compliance, reduced side effects, and controlled release of active ingredients. Drug-in-adhesive patches, matrix patches, microneedle patches, and reservoir membrane patches are available and are used according to medical requirements. The preference for transdermal patches is mainly due to their non-invasive nature and ease of application. They are suitable for patients experiencing difficulties swallowing pills or for those with gastrointestinal issues that may affect the absorption of medications. Transdermal semisolids include gels, creams, and ointments formulated with drugs that are absorbed through the skin into the systemic circulation. These dosage forms offer benefits such as easy application and removal, localized treatment without systemic side effects for certain conditions, and flexibility in formulation. Transdermal patches provide more consistent drug release than semisolids since they possess a controlled-release mechanism. Additionally, patches show better adhesion to the skin surface than semisolids, which may require frequent reapplication of the gels or creams.

Application: Need for minimally invasive drug delivery systems for management of cardiovascular diseases

Transdermal drug delivery systems are preferred in treating cardiovascular diseases such as angina pectoris or hypertension due to their ability to maintain constant plasma medication levels with fewer side effects. Nitroglycerin patches have been extensively used for angina patients, offering continuous relief without the need for frequent oral administration. TDDS displays an enhanced potential in managing central nervous system disorders, including Parkinson's disease and Alzheimer's disease, by maintaining steady concentrations of drugs. The continuous delivery minimizes fluctuations observed with oral medications, which can lead to breakthrough symptoms or side effects. Hormonal applications of TDDS include contraception, hormone replacement therapy (HRT), and testosterone supplementation. Transdermal patches offer advantages in maintaining steady hormone levels, reducing side effects, and improving patient compliance. Transdermal systems have gained popularity in managing chronic pain conditions, including musculoskeletal disorders or cancer-related pain, due to their ability to deliver analgesics directly to the affected area for long durations while minimizing systemic side effects. Transdermal estrogen therapy is essential for hormone replacement therapy for menopausal symptoms or osteoporosis management in postmenopausal women.

End-User: Preference for self-administration of drugs leading to demand for drug delivery systems that can be implemented in home care settings

Transdermal drug delivery systems are being utilized within particular innovative clinics for skin care and are implemented into the more effective health care system. With the growing understanding of drug delivery and the continued efforts of medical doctors, engineers, and scientists to advance this technology, an ultrasound-based transdermal delivery platform is expected to be a step closer to clinical applications. Clinical impact relies on a transdermal delivery system that administers drugs safely and effectively, is low-cost and easy to use, and is designed for self-administration at home. Transdermal drug delivery has recently gained popularity due to its unique and advantageous properties, which provide prospective benefits over conventional routes of drug administration in the therapy of numerous illnesses in hospital settings. Hospitals and clinics serve several patients in rural regions, particularly senior populations. These pharmacists help patients at a higher risk of medication interactions or illness complications due to a lack of control over their condition.

Regional Insights

The transdermal drug delivery market is evolving in the Americas due to its well-established healthcare infrastructure and research & development activities. Regulatory bodies in the Americas ensure adherence to standard guidelines while approving new products, resulting in the development of innovative transdermal technologies. The APAC region has a growing demand for advanced healthcare technologies due to increasing disposable incomes, population aging, and the need for efficient treatments. The transdermal drug delivery system market is growing in the EMEA region due to the presence of pharmaceutical industries, increased healthcare spending, and the rapid expansion of its manufacturing capabilities for transdermal systems. Moreover, the increasing adoption of personalized medicine and targeted therapies presents further prospects for TDDS systems tailored to specific patient populations or disease conditions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Transdermal Drug Delivery System Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Transdermal Drug Delivery System Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Transdermal Drug Delivery System Market, highlighting leading vendors and their innovative profiles. These include 3M Company, AdhexPharma, SAS, Bayer AG, Biotts Inc., Boehringer Ingelheim International GmbH, DuPont de Nemours, Inc., Gensco Pharma, Hisamitsu Pharmaceutical Co., Inc., IBSA Farmaceutici Italia Srl, IntelGenx Corp., Johnson & Johnson Services, Inc., Kindeva Drug Delivery L.P., Lavipharm S.A., Lead Chemical Co., Ltd., Luye Life Sciences Group, Medherant Limited, Nitto Denko Corporation, Novartis International AG, Nutriband Inc., Purdue Pharma L.P., Sorrento Therapeutics, Inc., Sparsha Pharma International Pvt. Ltd., Starton Therapeutics, Toa Eiyo Ltd., Toyo Ink SC Holdings Co., Ltd., Transdermal Therapeutics, Inc., UCB S.A., Viatris Inc., Zhongshan Senwell Bio Technology Co., Ltd., and Zynerba Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Transdermal Drug Delivery System Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Transdermal Patches
      • Drug-In-Adhesive Patches
      • Matrix Patches
      • Microneedle Patches
      • Reservoir Membrane Patches
    • Transdermal Semisolids
      • Gels
      • Ointments
      • Sprays
  • Application
    • Cardiovascular Diseases
    • Central Nervous System Disorders
    • Hormonal Applications
    • Pain Management
    • Transdermal Estrogen Therapy
  • End User
    • Home Care Settings
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Transdermal Drug Delivery System Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Transdermal Drug Delivery System Market?

3. What are the technology trends and regulatory frameworks in the Transdermal Drug Delivery System Market?

4. What is the market share of the leading vendors in the Transdermal Drug Delivery System Market?

5. Which modes and strategic moves are suitable for entering the Transdermal Drug Delivery System Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and the need for effective drug delivery
      • 5.1.1.2. Surging adoption of third-generation transdermal drug delivery system
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with irritation or skin sensitivity over patch usage
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research & development in transdermal drug delivery system
      • 5.1.3.2. Inorganic growth strategies between pharmaceutical companies and TDDS vendors
    • 5.1.4. Challenges
      • 5.1.4.1. Probable risk of drug failure through transdermal systems and product recalls
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Ongoing regulatory and government approvals for transdermal patches
    • 5.2.2. Application: Need for minimally invasive drug delivery systems for management of cardiovascular diseases
    • 5.2.3. End-User: Preference for self-administration of drugs leading to demand for drug delivery systems that can be implemented in home care settings
  • 5.3. Market Trend Analysis
    • 5.3.1. Potential power of market players and surge in regulatory approvals in the American region
    • 5.3.2. Surging healthcare spendings and inclusion of overseas players in the APAC region
    • 5.3.3. Persistent research activities and the growing burden of chronic disease in the EMEA region.
    • 5.3.4. Revolutionizing transdermal drug delivery with electronic skin
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis

6. Transdermal Drug Delivery System Market, by Type

  • 6.1. Introduction
  • 6.2. Transdermal Patches
  • 6.3. Transdermal Semisolids

7. Transdermal Drug Delivery System Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiovascular Diseases
  • 7.3. Central Nervous System Disorders
  • 7.4. Hormonal Applications
  • 7.5. Pain Management
  • 7.6. Transdermal Estrogen Therapy

8. Transdermal Drug Delivery System Market, by End User

  • 8.1. Introduction
  • 8.2. Home Care Settings
  • 8.3. Hospitals & Clinics

9. Americas Transdermal Drug Delivery System Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Transdermal Drug Delivery System Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Transdermal Drug Delivery System Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease
    • 12.3.2. Satio Wins USD 3.5 Million Contract To Develop At-Home Transdermal Drug Delivery Device
    • 12.3.3. LTS Completes Its Entry Into Large Molecule Drug Delivery With The Acquisition Of The Sorrel Wearable Injection Device Business
    • 12.3.4. DifGen Pharmaceuticals Acquires Aveva Drug Delivery Services Inc.
    • 12.3.5. Zydus Lifesciences gets Final Approval from the U.S. FDA to Market Estradiol Transdermal System
    • 12.3.6. Kindeva Merges with Meridian to Create Global CDMO Specializing in Drug-Device Combinations
    • 12.3.7. LTS Lohmann Leads Investment in Needle-Free Delivery Specialist
    • 12.3.8. Love Pharma Moves To Buy Transdermal Opioid-Use Disorder Player
    • 12.3.9. Corium Launches ADLARITY (donepezil transdermal system) for Patients with Alzheimer's Dementia
    • 12.3.10. Lowenstein Represents Pharma Tech LTS Lohmann Therapy Systems, Corp. in Acquisition of Tapemark Inc.

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio